INTRODUCTION
Retinitis pigmentosa (RP) is known to be caused by various ge netic changes in the components of the phototransduction pa thway. Some genetic changes may alter rod cells to be more susceptible to oxidative damage in the retina, which is exposed directly to the effects of light, leading to progressive retinal de generation (1, 2) . In other genetic mutations, rod cells may die from other primary processes; and then when the rod cells die, the oxygen content in the retina rises, causing oxidative stress and secondary degeneration of the remaining cone cells. The retina is highly metabolically active, and is therefore prone to oxidative damage. Various antioxidants have been considered as possible candidates that might delay this progression. There have been numerous reports on the effects of antioxidants in delaying the degeneration of photoreceptors in animal models of RP (3) . Antioxidant supplementation has been found to be effective in the intervention of atrophic agerelated macular degeneration (4) . Human clinical trials for antioxidants such as vitamins A and E, lutein, and docosahexaenoic acid have been conducted for RP with some beneficial effects noted (58). Ad ditionally, continuous modifications of antioxidant dosages and regimens have been tried as possible candidates for nutri tional supplementation in RP. Recently, patients consuming a diet rich in omega3 fatty acids and receiving 15,000 IU vitamin A daily were found to have a slower progression in decline of vi sual acuity over 4 to 6 yr (9), raising hope for a possible delay of progression in RP patients.
Chlorogenic acid (CGA) is a polyphenol found in various ag ricultural products such as coffee, beans, potatoes, and apples, and is formed by the esterification of caffeic and quinic acids. The antibacterial, antiinflammatory, antioxidant, and anti carcinogenic activities of CGA have been demonstrated in many studies (1013). CGA showed an antioxidant effect in vitro (14) , in cultured human endothelial cells (15) , and in rat models of ischemia/reperfusion injury to the liver (16) . The beneficial ef fect of CGA in coffee has been suggested in a human study mon itoring the oxidation of proteins, DNA membrane lipids, and other redox biomarkers (17) . Several studies have also demon strated its neuroprotective effect (18, 19) .
Multifocal electroretinography (mERG) has recently been evaluated as an objective electrophysiological method to evalu ate changes in retinal function in RP patients (20 , ERG, and contrast sensitivity (Vistech 6500 chart, Vistech Con sultants, Inc., Dayton, OH, USA) were measured at baseline and then measured again after 3 months of CGA supplementation. RP patients with a residual visual field of less than 10 degrees in any direction on the visual field examination, a best corrected visual acuity of less than 50 ETDRS letters, a history of CGA sup plementation within the prior 3 months, or abnormal liver en zyme (aspartate and alanine aminotrasferase > 40 IU/L, alka line phosphatase > 130 IU/L), creatinine (> 1.4 mg/dL), or blood urea nitrogen levels ( > 26 mg/dL) suggestive of liver or kidney dysfunction were excluded from the study.
MATERIALS AND METHODS

Study design
The amplitude of each ring on mERG was evaluated as the primary outcome measure. The eye with the larger amplitude on ring 1 of mERG was selected for analysis. Additionally, the total point score on HFA with target size III was used for the vi sual field evaluation. Fullfield ERG followed the guidelines of the International Society for Clinical Electrophysiology of Vi sion (ISCEV) (21); rodspecific and standard bright flash ERG were both recorded after a minimum of 20 min of dark adapta tion, and the photopic 30 Hz flicker and single flash cone re sponse was recorded following 10 min of light adaptation. The fullfield rod, cone and combined response amplitude was also studied as a secondary outcome measure. The log10 (contrast sensitivity) at each spatial frequency (1.5, 3, 6, 12, and 18 cycles/ degree) was also used as a secondary outcome measure. Any systemic adverse effects and subjective improvement of vision were also evaluated.
Statistical analyses
IBM SPSS Statistics 21 for Windows (IBM, Armonk, NY, USA) was used for statistical analyses. The Wilcoxon signedrank test was used for analysis of parameters before and after CGA sup plementation. A P value < 0.05 was considered statistically sig nificant.
Ethics statement
The study protocol was approved by the institutional review board of Seoul National University Hospital (IRB No. 1008131 329), and the study conformed to the Declaration of Helsinki. Informed consent was confirmed by the board. 
RESULTS
The demographic characteristics of the study patients are listed in Table 1 . The mean age of the patients included in the study was 31.7 ± 9.9 yr. The mean visual acuity was 77.3 ± 9.0 letters. The pre and posttreatment measurements are compared in Table 2 . There was no significant change in best corrected visu al acuity, total point score on HFA, rod, cone and combined re sponse amplitude on standard ERG, or contrast sensitivity; how ever, the amplitude of ring 5 on mERG was significantly higher after 3 months of CGA supplementation (7.2 ± 9.5 vs 8.3 ± 10.8 nV/deg 2 , mean ± standard deviation, P = 0.022, Wilcoxon sign edrank test) (Fig. 1) .
No systemic adverse events were noted with 3 months' sup plementation of CGA. Five patients expressed a subjective im provement of visual function, while 12 patients said they expe rienced no change. No patients noticed deterioration of visual function during the study period.
DISCUSSION
This study demonstrated that CGA significantly increased the amplitude of mERG, raising the possibility of a beneficial effect on the peripheral area at the margins of the retinal degenera tion. However, this study failed to show a significant improve ment in visual outcome measurements after CGA supplemen tation.
Considering the pathophysiology of photoreceptor cell dam age in hereditary retinal degeneration such as RP, various anti oxidants have been recommended to delay progression in these patients. However, there are difficulties in evaluating the effect on the degree of progression for slowly progressing diseases like RP, as conducting clinical trials for extended periods of time and controlling dietary intake is challenging. Therefore, the ef fect of antioxidants in RP patients is generally based on theo retical background, while the evidence from clinical trials is sparse. Vitamin A has been found to decrease the rate of de cline in ERG amplitude and marginally affect the rate of decline in the visual field area (22) . Docosahexaenoic acid, an omega3
http://dx.doi.org/10.3346/jkms.2014.29.1.117 fatty acid, was found to have an additional benefit in patients naïve to vitamin A supplementation in the initial 2 yr (8). Lutein supplementation slowed the loss of the midperipheral visual field in nonsmoking adults with RP taking vitamin A (5).
Peripheral ring 5 amplitude on mERG increased with CGA intake in our study. In a previous study (20) , mERG was sug gested as an effective tool for the longterm followup of disease progression and as an objective outcome measure in studies evaluating treatment outcome in RP patients. Ring 5 amplitude was found to be strongly correlated with the scotopic ERG mixed conerod response amplitude, but only mildly correlated with the visual field area. Other previous studies evaluating the ef fect of antioxidants in RP have not utilized mERG as a visual function evaluation tool (59). This increase in amplitude with CGA intake may indicate the possibility of a peripheral scotopic functional improvement effect, and raises the necessity of a longterm study verifying this effect of CGA using other more gross measurement tools, such as visual field measurement. Changes in mERG could be detected in Korean RP patients, who had been reported to have more advanced peripheral vi sual field defects, while central vision was more preserved (23); these patients may be possible candidates to benefit most from CGA supplementation to improve peripheral visual function.
Previous studies that have noted the beneficial effect of anti oxidants on the progression of RP have also identified improved visual function at the periphery of the retina, which is the site where degeneration occurs. Berson et al. (5) identified that lu tein supplementation of 12 mg/d slowed the loss of the mid peripheral visual field in nonsmoking adults with RP taking vi tamin A. Our finding of improvement in the mostperipheral ring 5 amplitude on mERG is consistent with this hypothesis. There has only been 1 study to date that has reported a benefit in the preservation of central visual function, which was a long term study of 4 to 6 yr of omega3 supplementation in RP pa tients taking vitamin A (9). Parameters associated with central visual function such as total point score on the central visual field examination on HFA, contrast sensitivity, and photopic 30Hz flicker amplitude on ERG need a longer followup time, and as expected, showed no significant change with shortterm CGA supplementation. In order to evaluate the possible bene fits to central visual function, a longterm study with a supple mentation period of several years should be conducted.
There are some shortcomings in this study. The followup period was short to evaluate the effects of nutrition supplemen tation, and the longterm benefit effect remains to be clarified. In addition, this study enrolled a small number of subjects with no control group, raising the possibility of bias. This study in cluded a heterogeneous study population with various degrees of RP progression, various genetic types, altered proteins, and mutations. Another possible factor is that the diseases of pa tients included in this study were not very advanced, and the patients had considerably larger residual visual function. A ran domized, placebocontrolled, longterm clinical trial in a large scale must be conducted to confirm the possible benefit of CGA supplementation in RP patients. Additionally, comparative stud ies among antioxidative agents may be necessary, and CGA should be considered as an antioxidant that can be used in the management of RP.
In conclusion, this study confirmed the objective effective ness of CGA in RP patients, and a clinical benefit of antioxidant supplementation in RP. The increased activity in the peripheral retina may raise the possibility of delaying the progressive de cline in visual function in hereditary retinal degeneration.
